TAVIST-1
LOE ApproachingNDAORALTABLET
Approved
Feb 1977
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 22h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TAVIST-1 is an oral tablet NDA approved by Novartis in 1977 with unknown mechanism of action and pharmacologic class. The drug's specific indications and mechanism remain undisclosed in available data. Patient population and clinical utility cannot be determined without additional therapeutic information.
LOE Approaching
Product is in LOE-approaching stage with moderate competitive pressure (30%), indicating shrinking commercial opportunity and likely team consolidation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings and approaching LOE indicate this product offers limited career growth and stability. Roles available would focus on defending market share and managing generic transition rather than expansion.
Brand ManagerField Sales Representative
Worked on TAVIST-1 at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.